Merus
MRUS · NASDAQ
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Merus N.V. is a Dutch biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company is particularly known for its bispecific antibody technology, designed to selectively activate the immune system against cancer cells. Merus N.V. concentrates on developing treatments that can offer new hope to patients suffering from various types of cancer, including those who have failed other therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
260
Headquarters
Utrecht